Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8721518 | Clinical Immunology | 2017 | 23 Pages |
Abstract
Reliable immunologic biomarkers able to monitor disease course during multiple sclerosis (MS) are still missing. We aimed at identifying possible immunometabolic biomarkers able to predict the clinical outcome in MS patients during treatment with interferon (IFN)-beta-1a. We measured in 45 relapsing-remitting (RR) MS patients, blood circulating levels of several immunometabolic markers, at enrolment, and correlated their levels to disease activity and progression over time. Higher levels of interleukin (IL)-6, soluble-CD40-ligand (sCD40L) and leptin at baseline associated with a higher relapse rate and a greater risk of experiencing at least one relapse in the following year. Higher values of soluble tumor necrosis factor receptor (sTNF-R) and leptin at baseline were predictive of a higher number of lesions in the following one-year of follow up. In conclusion, our data suggest that an immunometabolic profiling measuring IL-6, sCD40L, leptin and sTNF-R at baseline, could represent a useful tool to predict disease course in RRMS patients during treatment with IFN-beta-1a.
Keywords
T helpersTNF-RIL-6sCD40LRRMsTregsICAM-1MCP-1EAEEDSSMPOexperimental autoimmune encephalomyelitisMRIinterferon beta-1ainterleukinMagnetic resonance imagingautoimmunityCNScentral nervous systembody mass indexBMILeptinRegulatory T Expanded Disability Status Scalerelapsing-remitting multiple sclerosisMultiple sclerosissoluble intercellular adhesion molecule 1myeloperoxidaseRate Ratiomonocyte chemoattractant protein-1Soluble tumor necrosis factor receptor
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Roberta Lanzillo, Fortunata Carbone, Mario Quarantelli, Dario Bruzzese, Antonio Carotenuto, Veronica De Rosa, Alessandra Colamatteo, Teresa Micillo, Carla De Luca Picione, Francesco Saccà , Anna De Rosa, Marcello Moccia, Vincenzo Brescia Morra,